{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "COVID-19",
      "cytokines",
      "melatonin",
      "melatonin receptors",
      "outpatient"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33759236",
  "DateCompleted": {
    "Year": "2021",
    "Month": "07",
    "Day": "28"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "12",
    "Day": "07"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "04",
        "Day": "26"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "e12732",
      "10.1111/jpi.12732"
    ],
    "Journal": {
      "ISSN": "1600-079X",
      "JournalIssue": {
        "Volume": "71",
        "Issue": "1",
        "PubDate": {
          "Year": "2021",
          "Month": "Aug"
        }
      },
      "Title": "Journal of pineal research",
      "ISOAbbreviation": "J Pineal Res"
    },
    "ArticleTitle": "Melatonin multifaceted pharmacological actions on melatonin receptors converging to abrogate COVID-19.",
    "Pagination": {
      "StartPage": "e12732",
      "MedlinePgn": "e12732"
    },
    "Abstract": {
      "AbstractText": [
        "Data indicate that controlling inflammatory responses to COVID-19 may be as important as antiviral therapies or could be an important adjunctive approach. Melatonin possesses anti-inflammation, antioxidation, and immune-enhancing features directly and/or indirectly through its own receptor signaling and is therefore well suited to reduce the severity of COVID-19. Studies have proposed that melatonin regulates COVID-19-associated proteins directly through regulation of molecules such as calmodulin (CALM) 1 and CALM 2, calreticulin (CalR), or myeloperoxidase (MPO) and/or indirectly through actions on GPCR (eg, MTNR1A, MTNR1B) and nuclear (eg, ROR\u03b1, ROR\u03b2) melatonin receptor signaling. However, the exact mechanism(s) and doses by which melatonin reduces the severity of COVID-19 is still open for debate, warranting the need for further testing of melatonin in placebo-controlled randomized clinical trials for COVID-19."
      ],
      "CopyrightInformation": "\u00a9 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA."
          }
        ],
        "LastName": "Reynolds",
        "ForeName": "Jessica L",
        "Initials": "JL"
      },
      {
        "Identifier": [
          "0000-0002-9697-2044"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA."
          },
          {
            "Identifier": [],
            "Affiliation": "Interdepartmental Graduate Program in Neuroscience, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA."
          }
        ],
        "LastName": "Dubocovich",
        "ForeName": "Margarita L",
        "Initials": "ML"
      }
    ],
    "GrantList": [
      {
        "GrantID": "KL2 TR001413",
        "Acronym": "TR",
        "Agency": "NCATS NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R01 AI129649",
        "Acronym": "AI",
        "Agency": "NIAID NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "UL1 TR001412",
        "Acronym": "TR",
        "Agency": "NCATS NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "J Pineal Res",
    "NlmUniqueID": "8504412",
    "ISSNLinking": "0742-3098"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Anti-Inflammatory Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Receptors, Melatonin"
    },
    {
      "RegistryNumber": "JL5DK93RCL",
      "NameOfSubstance": "Melatonin"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Anti-Inflammatory Agents"
    },
    {
      "QualifierName": [
        "immunology",
        "metabolism",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Host-Pathogen Interactions"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Melatonin"
    },
    {
      "QualifierName": [
        "agonists",
        "metabolism"
      ],
      "DescriptorName": "Receptors, Melatonin"
    },
    {
      "QualifierName": [
        "immunology",
        "pathogenicity"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Severity of Illness Index"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Signal Transduction"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Drug Treatment"
    }
  ],
  "CoiStatement": "The authors declare no conflict of interest."
}